Eksobionics Eksoskeleton NR for Parkinson's (NCT06225830)
Improve walking via robotic exoskeleton
- Trial ID
- NCT06225830
- Official Title
- Utilization of Robotic EksoSkeleton to Achieve High Dosing, Intensity, and Complexity of Gait in Treatment of People With Parkinson's Disease
- Goal
- Improve walking via robotic exoskeleton
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Albert Einstein Healthcare Network
- Study Type
- INTERVENTIONAL
- Enrollment
- 24 participants
- Conditions
- Parkinson Disease
- Interventions
- Eksobionics Eksoskeleton NR
Summary For Families
The goal is to improve walking and balance by giving people with Parkinson's much more high-intensity, complex gait practice than they can do safely on their own. The approach uses the Ekso wearable robotic exoskeleton to support and assist hip and leg movements so you can stand and take many more steps at a hard effort, helping retrain walking circuits and build endurance; sessions are 45 to 60 minutes with about 30 minutes at RPE 14 to 17, and the therapy is meant to complement your usual Parkinson's medications. They are enrolling adults over 18 with a physician diagnosis of idiopathic Parkinson's who report walking or balance problems, can tolerate at least 15 minutes upright and use a front-wheeled walker, and who fit device limits (under 220 pounds, roughly 5'0" to 6'4"), while people with major cognitive, neurological, cardiovascular, or musculoskeletal issues that make exoskeleton use unsafe are excluded.
Locations
- Jefferson Moss-Magee Rehabilitation - Elkins Park, Elkins Park, Pennsylvania, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Eksobionics Eksoskeleton NR. The goal is to improve walking and balance by giving people with Parkinson's much more high-intensity, complex gait practice than they can do safely on their own. The approach uses the Ekso wearable robotic exoskeleton to support and assist hip and leg movements so you can stand and take many more steps at a hard effort, helping retrain walking circuits and build endurance; sessions are 45 to 60 minutes with about 30 minutes at RPE 14 to 17, and the therapy is meant to complement your usual Parkinson's medications. They are enrolling adults over 18 with a physician diagnosis of idiopathic Parkinson's who report walking or balance problems, can tolerate at least 15 minutes upright and use a front-wheeled walker, and who fit device limits (under 220 pounds, roughly 5'0" to 6'4"), while people with major cognitive, neurological, cardiovascular, or musculoskeletal issues that make exoskeleton use unsafe are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 2 years.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.
- How many visits does this trial involve?
- You will attend Ekso treatment sessions twice per week for 8 weeks, and there are Four (4) study-related assessment sessions (Evaluation/1st visit, re-evaluation at visit 9, discharge/visit 17, and a 3-month follow-up).
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Questionnaires & surveys (non-invasive). Confirm the full schedule with the study coordinator.